156 related articles for article (PubMed ID: 31084438)
1. The correlation between metastasis-free survival and overall survival in non-metastatic castration resistant prostate cancer patients from the Medical Data Vision claims database in Japan.
Mori A; Hashimoto K; Koroki Y; Wu DB; Masumori N
Curr Med Res Opin; 2019 Oct; 35(10):1745-1750. PubMed ID: 31084438
[No Abstract] [Full Text] [Related]
2. Assessing the correlation between second progression-free survival (PFS2) and overall survival (OS) in advanced prostate cancer patients using medical data vision (MDV) claims database in Japan.
Shiota M; De Moor R; Koroki Y; Yu DY; Wu DB
Curr Med Res Opin; 2022 Aug; 38(8):1351-1359. PubMed ID: 35770513
[TBL] [Abstract][Full Text] [Related]
3. Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer.
Mori K; Kimura T; Fukuokaya W; Iwatani K; Sakanaka K; Kurokawa G; Yanagisawa T; Sasaki H; Miki J; Shimomura T; Miki K; Hatano T; Endo K; Egawa S
Int J Clin Oncol; 2020 Mar; 25(3):479-485. PubMed ID: 31512007
[TBL] [Abstract][Full Text] [Related]
4. Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer.
Freedland SJ; Pilon D; Bhak RH; Lefebvre P; Li S; Young-Xu Y
Urol Oncol; 2020 Dec; 38(12):930.e13-930.e21. PubMed ID: 32739230
[TBL] [Abstract][Full Text] [Related]
5. Relationship Between Metastasis-free Survival and Overall Survival in Patients With Nonmetastatic Castration-resistant Prostate Cancer.
Smith MR; Mehra M; Nair S; Lawson J; Small EJ
Clin Genitourin Cancer; 2020 Apr; 18(2):e180-e189. PubMed ID: 31980408
[TBL] [Abstract][Full Text] [Related]
6. Does docetaxel prolong survival of patients with non-metastatic castration-resistant prostate cancer?
Ito K; Kimura T; Onuma H; Tabata R; Shimomura T; Miki K; Tomita M; Egawa S
Prostate; 2018 May; 78(7):498-505. PubMed ID: 29473179
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Factors Predicting Disease Progression in Japanese Patients With Non-Metastatic Castration-resistant Prostate Cancer.
Miyake H; Watanabe K; Matsushita Y; Watanabe H; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
Anticancer Res; 2020 Feb; 40(2):1101-1106. PubMed ID: 32014960
[TBL] [Abstract][Full Text] [Related]
8. Is time to castration resistant prostate cancer a potential intermediate end-point for time to metastasis among men initiating androgen deprivation therapy for non-metastatic prostate cancer with rapid PSA doubling time (<9 months)?
Klaassen Z; Howard L; Wallis CJD; Janes JL; De Hoedt A; Aronson WJ; Polascik TJ; Amling CJ; Kane CJ; Cooperberg MR; Terris MK; Wu Y; Freedland SJ
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):151-155. PubMed ID: 36050455
[TBL] [Abstract][Full Text] [Related]
9. Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer.
Xie W; Ravi P; Buyse M; Halabi S; Kantoff P; Sartor O; Soule H; Clarke N; Dignam J; James N; Fizazi K; Gillessen S; Mottet N; Murphy L; Parulekar W; Sandler H; Tombal B; Williams S; Sweeney CJ
Ann Oncol; 2024 Mar; 35(3):285-292. PubMed ID: 38061427
[TBL] [Abstract][Full Text] [Related]
10. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer.
Small EJ; Saad F; Chowdhury S; Oudard S; Hadaschik BA; Graff JN; Olmos D; Mainwaring PN; Lee JY; Uemura H; De Porre P; Smith AA; Zhang K; Lopez-Gitlitz A; Smith MR
Ann Oncol; 2019 Nov; 30(11):1813-1820. PubMed ID: 31560066
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Vintage Hormone Therapy as Alternative Androgen Deprivation Therapy for Non-metastatic Castration-resistant Prostate Cancer.
Iwamoto H; Kano H; Shimada T; Naito R; Makino T; Kadamoto S; Yaegashi H; Shigehara K; Izumi K; Kadonoa Y; Mizokami A
In Vivo; 2021; 35(2):1247-1252. PubMed ID: 33622927
[TBL] [Abstract][Full Text] [Related]
12. Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: A tertiary academic center experience.
Afshar M; Evison F; James ND; Patel P
Urol Oncol; 2015 Aug; 33(8):338.e1-7. PubMed ID: 26059077
[TBL] [Abstract][Full Text] [Related]
13. Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial.
Rathkopf DE; Beer TM; Loriot Y; Higano CS; Armstrong AJ; Sternberg CN; de Bono JS; Tombal B; Parli T; Bhattacharya S; Phung D; Krivoshik A; Scher HI; Morris MJ
JAMA Oncol; 2018 May; 4(5):694-701. PubMed ID: 29522174
[TBL] [Abstract][Full Text] [Related]
14. A 2-Gene Panel Derived From Prostate Cancer-Enhanced Transcripts in Whole Blood Is Prognostic for Survival and Predicts Treatment Benefit in Metastatic Castration-Resistant Prostate Cancer.
Heck MM; Thalgott M; Schmid SC; Oh WK; Gong Y; Wang L; Zhu J; Seitz AK; Porst D; Höppner M; Retz M; Gschwend JE; Nawroth R
Prostate; 2016 Sep; 76(13):1160-8. PubMed ID: 27198487
[TBL] [Abstract][Full Text] [Related]
15. A retrospective study on the incidence, management and risk factors of skin rash in patients with advanced prostate cancer in Japan.
De Moor R; Koroki Y; Wu DB; Yu DY; Tohyama M; Ohyama C
BMC Urol; 2023 Apr; 23(1):73. PubMed ID: 37118710
[TBL] [Abstract][Full Text] [Related]
16. The impact of time to metastasis on overall survival in patients with prostate cancer.
Frees S; Akamatsu S; Bidnur S; Khalaf D; Chavez-Munoz C; Struss W; Eigl BJ; Gleave M; Chi KN; So A
World J Urol; 2018 Jul; 36(7):1039-1046. PubMed ID: 29488095
[TBL] [Abstract][Full Text] [Related]
17. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.
Xie W; Regan MM; Buyse M; Halabi S; Kantoff PW; Sartor O; Soule H; Clarke NW; Collette L; Dignam JJ; Fizazi K; Paruleker WR; Sandler HM; Sydes MR; Tombal B; Williams SG; Sweeney CJ;
J Clin Oncol; 2017 Sep; 35(27):3097-3104. PubMed ID: 28796587
[TBL] [Abstract][Full Text] [Related]
18. New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes.
Di Nunno V; Mollica V; Santoni M; Gatto L; Schiavina R; Fiorentino M; Brunocilla E; Ardizzoni A; Massari F
Clin Genitourin Cancer; 2019 Oct; 17(5):e871-e877. PubMed ID: 31378578
[TBL] [Abstract][Full Text] [Related]
19. Metastasis-free survival as a new endpoint in castration- -resistant prostate cancer.
Kuzma M; Kliment J
Bratisl Lek Listy; 2020; 121(6):411-414. PubMed ID: 32484704
[TBL] [Abstract][Full Text] [Related]
20. Risk Factors for Poor Survival in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel in Japan.
Yasuoka S; Yuasa T; Ogawa M; Komai Y; Numao N; Yamamoto S; Kondo Y; Yonese J
Anticancer Res; 2019 Oct; 39(10):5803-5809. PubMed ID: 31570485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
